Table of Content

1 Study Coverage
1.1 Adalimumab (Humira) and Biosimilar Product Introduction
1.2 Market by Type
1.2.1 Global Adalimumab (Humira) and Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Syringe
1.2.3 Pen
1.3 Market by Application
1.3.1 Global Adalimumab (Humira) and Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Adalimumab (Humira) and Biosimilar Sales Estimates and Forecasts 2018-2034
2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Region
2.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2018 VS 2024 VS 2034
2.2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Region (2018-2023)
2.2.3 Global Adalimumab (Humira) and Biosimilar Revenue by Region (2024-2034)
2.2.4 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2018-2034)
2.3 Global Adalimumab (Humira) and Biosimilar Sales Estimates and Forecasts 2018-2034
2.4 Global Adalimumab (Humira) and Biosimilar Sales by Region
2.4.1 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2018 VS 2024 VS 2034
2.4.2 Global Adalimumab (Humira) and Biosimilar Sales by Region (2018-2023)
2.4.3 Global Adalimumab (Humira) and Biosimilar Sales by Region (2024-2034)
2.4.4 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Adalimumab (Humira) and Biosimilar Sales by Manufacturers
3.1.1 Global Adalimumab (Humira) and Biosimilar Sales by Manufacturers (2018-2023)
3.1.2 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Adalimumab (Humira) and Biosimilar in 2024
3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturers
3.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturers (2018-2023)
3.2.2 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Adalimumab (Humira) and Biosimilar Revenue in 2024
3.3 Global Key Players of Adalimumab (Humira) and Biosimilar, Industry Ranking, 2021 VS 2024 VS 2023
3.4 Global Adalimumab (Humira) and Biosimilar Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Product Offered and Application
3.8 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Adalimumab (Humira) and Biosimilar Sales by Type
4.1.1 Global Adalimumab (Humira) and Biosimilar Historical Sales by Type (2018-2023)
4.1.2 Global Adalimumab (Humira) and Biosimilar Forecasted Sales by Type (2024-2034)
4.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2034)
4.2 Global Adalimumab (Humira) and Biosimilar Revenue by Type
4.2.1 Global Adalimumab (Humira) and Biosimilar Historical Revenue by Type (2018-2023)
4.2.2 Global Adalimumab (Humira) and Biosimilar Forecasted Revenue by Type (2024-2034)
4.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2034)
4.3 Global Adalimumab (Humira) and Biosimilar Price by Type
4.3.1 Global Adalimumab (Humira) and Biosimilar Price by Type (2018-2023)
4.3.2 Global Adalimumab (Humira) and Biosimilar Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Adalimumab (Humira) and Biosimilar Sales by Application
5.1.1 Global Adalimumab (Humira) and Biosimilar Historical Sales by Application (2018-2023)
5.1.2 Global Adalimumab (Humira) and Biosimilar Forecasted Sales by Application (2024-2034)
5.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2034)
5.2 Global Adalimumab (Humira) and Biosimilar Revenue by Application
5.2.1 Global Adalimumab (Humira) and Biosimilar Historical Revenue by Application (2018-2023)
5.2.2 Global Adalimumab (Humira) and Biosimilar Forecasted Revenue by Application (2024-2034)
5.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2034)
5.3 Global Adalimumab (Humira) and Biosimilar Price by Application
5.3.1 Global Adalimumab (Humira) and Biosimilar Price by Application (2018-2023)
5.3.2 Global Adalimumab (Humira) and Biosimilar Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Adalimumab (Humira) and Biosimilar Market Size by Type
6.1.1 US & Canada Adalimumab (Humira) and Biosimilar Sales by Type (2018-2034)
6.1.2 US & Canada Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2034)
6.2 US & Canada Adalimumab (Humira) and Biosimilar Market Size by Application
6.2.1 US & Canada Adalimumab (Humira) and Biosimilar Sales by Application (2018-2034)
6.2.2 US & Canada Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2034)
6.3 US & Canada Adalimumab (Humira) and Biosimilar Market Size by Country
6.3.1 US & Canada Adalimumab (Humira) and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
6.3.2 US & Canada Adalimumab (Humira) and Biosimilar Sales by Country (2018-2034)
6.3.3 US & Canada Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Adalimumab (Humira) and Biosimilar Market Size by Type
7.1.1 Europe Adalimumab (Humira) and Biosimilar Sales by Type (2018-2034)
7.1.2 Europe Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2034)
7.2 Europe Adalimumab (Humira) and Biosimilar Market Size by Application
7.2.1 Europe Adalimumab (Humira) and Biosimilar Sales by Application (2018-2034)
7.2.2 Europe Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2034)
7.3 Europe Adalimumab (Humira) and Biosimilar Market Size by Country
7.3.1 Europe Adalimumab (Humira) and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
7.3.2 Europe Adalimumab (Humira) and Biosimilar Sales by Country (2018-2034)
7.3.3 Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Adalimumab (Humira) and Biosimilar Market Size
8.1.1 China Adalimumab (Humira) and Biosimilar Sales (2018-2034)
8.1.2 China Adalimumab (Humira) and Biosimilar Revenue (2018-2034)
8.2 China Adalimumab (Humira) and Biosimilar Market Size by Application
8.2.1 China Adalimumab (Humira) and Biosimilar Sales by Application (2018-2034)
8.2.2 China Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Adalimumab (Humira) and Biosimilar Market Size by Type
9.1.1 Asia Adalimumab (Humira) and Biosimilar Sales by Type (2018-2034)
9.1.2 Asia Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2034)
9.2 Asia Adalimumab (Humira) and Biosimilar Market Size by Application
9.2.1 Asia Adalimumab (Humira) and Biosimilar Sales by Application (2018-2034)
9.2.2 Asia Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2034)
9.3 Asia Adalimumab (Humira) and Biosimilar Sales by Region
9.3.1 Asia Adalimumab (Humira) and Biosimilar Revenue by Region: 2018 VS 2024 VS 2034
9.3.2 Asia Adalimumab (Humira) and Biosimilar Revenue by Region (2018-2034)
9.3.3 Asia Adalimumab (Humira) and Biosimilar Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Market Size by Type
10.1.1 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Market Size by Application
10.2.1 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Country
10.3.1 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
10.3.2 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Overview
11.1.3 AbbVie Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 AbbVie Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AbbVie Recent Developments
11.2 Eisai
11.2.1 Eisai Company Information
11.2.2 Eisai Overview
11.2.3 Eisai Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Eisai Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eisai Recent Developments
11.3 Cadila Healthcare
11.3.1 Cadila Healthcare Company Information
11.3.2 Cadila Healthcare Overview
11.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cadila Healthcare Recent Developments
11.4 Torrent Pharmaceuticals
11.4.1 Torrent Pharmaceuticals Company Information
11.4.2 Torrent Pharmaceuticals Overview
11.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Torrent Pharmaceuticals Recent Developments
11.5 Amgen
11.5.1 Amgen Company Information
11.5.2 Amgen Overview
11.5.3 Amgen Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Amgen Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Amgen Recent Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Information
11.6.2 Boehringer Ingelheim Overview
11.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Boehringer Ingelheim Recent Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Overview
11.7.3 Novartis Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Novartis Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Novartis Recent Developments
11.8 Samsung Bioepis
11.8.1 Samsung Bioepis Company Information
11.8.2 Samsung Bioepis Overview
11.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Samsung Bioepis Recent Developments
11.9 Viatris
11.9.1 Viatris Company Information
11.9.2 Viatris Overview
11.9.3 Viatris Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Viatris Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Viatris Recent Developments
11.10 Pfizer
11.10.1 Pfizer Company Information
11.10.2 Pfizer Overview
11.10.3 Pfizer Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Pfizer Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Pfizer Recent Developments
11.11 Fresenius Kabi
11.11.1 Fresenius Kabi Company Information
11.11.2 Fresenius Kabi Overview
11.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Fresenius Kabi Recent Developments
11.12 Coherus
11.12.1 Coherus Company Information
11.12.2 Coherus Overview
11.12.3 Coherus Adalimumab (Humira) and Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Coherus Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Coherus Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Adalimumab (Humira) and Biosimilar Industry Chain Analysis
12.2 Adalimumab (Humira) and Biosimilar Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Adalimumab (Humira) and Biosimilar Production Mode & Process
12.4 Adalimumab (Humira) and Biosimilar Sales and Marketing
12.4.1 Adalimumab (Humira) and Biosimilar Sales Channels
12.4.2 Adalimumab (Humira) and Biosimilar Distributors
12.5 Adalimumab (Humira) and Biosimilar Customers
13 Market Dynamics
13.1 Adalimumab (Humira) and Biosimilar Industry Trends
13.2 Adalimumab (Humira) and Biosimilar Market Drivers
13.3 Adalimumab (Humira) and Biosimilar Market Challenges
13.4 Adalimumab (Humira) and Biosimilar Market Restraints
14 Key Findings in The Global Adalimumab (Humira) and Biosimilar Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Adalimumab (Humira) and Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Syringe
Table 3. Major Manufacturers of Pen
Table 4. Global Adalimumab (Humira) and Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Adalimumab (Humira) and Biosimilar Revenue Grow Rate (CAGR) by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Adalimumab (Humira) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Adalimumab (Humira) and Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2018-2023)
Table 9. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2024-2034)
Table 10. Global Adalimumab (Humira) and Biosimilar Sales Grow Rate (CAGR) by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global Adalimumab (Humira) and Biosimilar Sales by Region (2018-2023) & (K Units)
Table 12. Global Adalimumab (Humira) and Biosimilar Sales by Region (2024-2034) & (K Units)
Table 13. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2018-2023)
Table 14. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2024-2034)
Table 15. Global Adalimumab (Humira) and Biosimilar Sales by Manufacturers (2018-2023) & (K Units)
Table 16. Global Adalimumab (Humira) and Biosimilar Sales Share by Manufacturers (2018-2023)
Table 17. Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Adalimumab (Humira) and Biosimilar Revenue Share by Manufacturers (2018-2023)
Table 19. Global Key Players of Adalimumab (Humira) and Biosimilar, Industry Ranking, 2021 VS 2024 VS 2023
Table 20. Adalimumab (Humira) and Biosimilar Price by Manufacturers 2018-2023 (US$/Unit)
Table 21. Global Adalimumab (Humira) and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Adalimumab (Humira) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab (Humira) and Biosimilar as of 2024)
Table 23. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Product Offered and Application
Table 25. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023) & (K Units)
Table 28. Global Adalimumab (Humira) and Biosimilar Sales by Type (2024-2034) & (K Units)
Table 29. Global Adalimumab (Humira) and Biosimilar Sales Share by Type (2018-2023)
Table 30. Global Adalimumab (Humira) and Biosimilar Sales Share by Type (2024-2034)
Table 31. Global Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Adalimumab (Humira) and Biosimilar Revenue Share by Type (2018-2023)
Table 34. Global Adalimumab (Humira) and Biosimilar Revenue Share by Type (2024-2034)
Table 35. Adalimumab (Humira) and Biosimilar Price by Type (2018-2023) & (US$/Unit)
Table 36. Global Adalimumab (Humira) and Biosimilar Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023) & (K Units)
Table 38. Global Adalimumab (Humira) and Biosimilar Sales by Application (2024-2034) & (K Units)
Table 39. Global Adalimumab (Humira) and Biosimilar Sales Share by Application (2018-2023)
Table 40. Global Adalimumab (Humira) and Biosimilar Sales Share by Application (2024-2034)
Table 41. Global Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Adalimumab (Humira) and Biosimilar Revenue Share by Application (2018-2023)
Table 44. Global Adalimumab (Humira) and Biosimilar Revenue Share by Application (2024-2034)
Table 45. Adalimumab (Humira) and Biosimilar Price by Application (2018-2023) & (US$/Unit)
Table 46. Global Adalimumab (Humira) and Biosimilar Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023) & (K Units)
Table 48. US & Canada Adalimumab (Humira) and Biosimilar Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 50. US & Canada Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023) & (K Units)
Table 52. US & Canada Adalimumab (Humira) and Biosimilar Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 54. US & Canada Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada Adalimumab (Humira) and Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 56. US & Canada Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 57. US & Canada Adalimumab (Humira) and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada Adalimumab (Humira) and Biosimilar Sales by Country (2018-2023) & (K Units)
Table 59. US & Canada Adalimumab (Humira) and Biosimilar Sales by Country (2024-2034) & (K Units)
Table 60. Europe Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023) & (K Units)
Table 61. Europe Adalimumab (Humira) and Biosimilar Sales by Type (2024-2034) & (K Units)
Table 62. Europe Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 63. Europe Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023) & (K Units)
Table 65. Europe Adalimumab (Humira) and Biosimilar Sales by Application (2024-2034) & (K Units)
Table 66. Europe Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 67. Europe Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe Adalimumab (Humira) and Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 69. Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 70. Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe Adalimumab (Humira) and Biosimilar Sales by Country (2018-2023) & (K Units)
Table 72. Europe Adalimumab (Humira) and Biosimilar Sales by Country (2024-2034) & (K Units)
Table 73. China Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023) & (K Units)
Table 74. China Adalimumab (Humira) and Biosimilar Sales by Type (2024-2034) & (K Units)
Table 75. China Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 76. China Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 77. China Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023) & (K Units)
Table 78. China Adalimumab (Humira) and Biosimilar Sales by Application (2024-2034) & (K Units)
Table 79. China Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 80. China Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023) & (K Units)
Table 82. Asia Adalimumab (Humira) and Biosimilar Sales by Type (2024-2034) & (K Units)
Table 83. Asia Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 84. Asia Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023) & (K Units)
Table 86. Asia Adalimumab (Humira) and Biosimilar Sales by Application (2024-2034) & (K Units)
Table 87. Asia Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 88. Asia Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia Adalimumab (Humira) and Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 90. Asia Adalimumab (Humira) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 91. Asia Adalimumab (Humira) and Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia Adalimumab (Humira) and Biosimilar Sales by Region (2018-2023) & (K Units)
Table 93. Asia Adalimumab (Humira) and Biosimilar Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023) & (K Units)
Table 95. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 97. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023) & (K Units)
Table 99. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 101. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2024-2034) & (K Units)
Table 107. AbbVie Company Information
Table 108. AbbVie Description and Major Businesses
Table 109. AbbVie Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. AbbVie Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. AbbVie Recent Developments
Table 112. Eisai Company Information
Table 113. Eisai Description and Major Businesses
Table 114. Eisai Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Eisai Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Eisai Recent Developments
Table 117. Cadila Healthcare Company Information
Table 118. Cadila Healthcare Description and Major Businesses
Table 119. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Cadila Healthcare Recent Developments
Table 122. Torrent Pharmaceuticals Company Information
Table 123. Torrent Pharmaceuticals Description and Major Businesses
Table 124. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Torrent Pharmaceuticals Recent Developments
Table 127. Amgen Company Information
Table 128. Amgen Description and Major Businesses
Table 129. Amgen Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Amgen Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Amgen Recent Developments
Table 132. Boehringer Ingelheim Company Information
Table 133. Boehringer Ingelheim Description and Major Businesses
Table 134. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Boehringer Ingelheim Recent Developments
Table 137. Novartis Company Information
Table 138. Novartis Description and Major Businesses
Table 139. Novartis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. Novartis Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Novartis Recent Developments
Table 142. Samsung Bioepis Company Information
Table 143. Samsung Bioepis Description and Major Businesses
Table 144. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 145. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Samsung Bioepis Recent Developments
Table 147. Viatris Company Information
Table 148. Viatris Description and Major Businesses
Table 149. Viatris Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 150. Viatris Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Viatris Recent Developments
Table 152. Pfizer Company Information
Table 153. Pfizer Description and Major Businesses
Table 154. Pfizer Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 155. Pfizer Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Pfizer Recent Developments
Table 157. Fresenius Kabi Company Information
Table 158. Fresenius Kabi Description and Major Businesses
Table 159. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 160. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Fresenius Kabi Recent Developments
Table 162. Coherus Company Information
Table 163. Coherus Description and Major Businesses
Table 164. Coherus Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 165. Coherus Adalimumab (Humira) and Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Coherus Recent Developments
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. Adalimumab (Humira) and Biosimilar Distributors List
Table 170. Adalimumab (Humira) and Biosimilar Customers List
Table 171. Adalimumab (Humira) and Biosimilar Market Trends
Table 172. Adalimumab (Humira) and Biosimilar Market Drivers
Table 173. Adalimumab (Humira) and Biosimilar Market Challenges
Table 174. Adalimumab (Humira) and Biosimilar Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Adalimumab (Humira) and Biosimilar Product Picture
Figure 2. Global Adalimumab (Humira) and Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Adalimumab (Humira) and Biosimilar Market Share by Type in 2024 & 2034
Figure 4. Syringe Product Picture
Figure 5. Pen Product Picture
Figure 6. Global Adalimumab (Humira) and Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Adalimumab (Humira) and Biosimilar Market Share by Application in 2024 & 2034
Figure 8. Ankylosing Spondylitis
Figure 9. Rheumatoid Arthritis
Figure 10. Crohn’s Disease
Figure 11. Other
Figure 12. Adalimumab (Humira) and Biosimilar Report Years Considered
Figure 13. Global Adalimumab (Humira) and Biosimilar Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Adalimumab (Humira) and Biosimilar Revenue 2018-2034 (US$ Million)
Figure 15. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 16. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2018-2034)
Figure 17. Global Adalimumab (Humira) and Biosimilar Sales 2018-2034 ((K Units)
Figure 18. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2018-2034)
Figure 19. US & Canada Adalimumab (Humira) and Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 20. US & Canada Adalimumab (Humira) and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Adalimumab (Humira) and Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 22. Europe Adalimumab (Humira) and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Adalimumab (Humira) and Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 24. China Adalimumab (Humira) and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Asia (excluding China) Adalimumab (Humira) and Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 26. Asia (excluding China) Adalimumab (Humira) and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Adalimumab (Humira) and Biosimilar Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2024
Figure 30. The Top 5 and 10 Largest Manufacturers of Adalimumab (Humira) and Biosimilar in the World: Market Share by Adalimumab (Humira) and Biosimilar Revenue in 2024
Figure 31. Global Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 32. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2034)
Figure 33. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 34. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2034)
Figure 35. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 36. US & Canada Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2034)
Figure 37. US & Canada Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 38. US & Canada Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2034)
Figure 39. US & Canada Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 40. US & Canada Adalimumab (Humira) and Biosimilar Revenue Share by Country (2018-2034)
Figure 41. US & Canada Adalimumab (Humira) and Biosimilar Sales Share by Country (2018-2034)
Figure 42. U.S. Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2034)
Figure 45. Europe Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 46. Europe Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2034)
Figure 47. Europe Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 48. Europe Adalimumab (Humira) and Biosimilar Revenue Share by Country (2018-2034)
Figure 49. Europe Adalimumab (Humira) and Biosimilar Sales Share by Country (2018-2034)
Figure 50. Germany Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 51. France Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 52. U.K. Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 53. Italy Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 54. Russia Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 55. China Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2034)
Figure 56. China Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 57. China Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2034)
Figure 58. China Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 59. Asia Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2034)
Figure 60. Asia Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 61. Asia Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2034)
Figure 62. Asia Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 63. Asia Adalimumab (Humira) and Biosimilar Revenue Share by Region (2018-2034)
Figure 64. Asia Adalimumab (Humira) and Biosimilar Sales Share by Region (2018-2034)
Figure 65. Japan Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 66. South Korea Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 67. China Taiwan Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 68. Southeast Asia Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 69. India Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2034)
Figure 71. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2034)
Figure 73. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Revenue Share by Country (2018-2034)
Figure 75. Middle East, Africa and Latin America Adalimumab (Humira) and Biosimilar Sales Share by Country (2018-2034)
Figure 76. Brazil Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 77. Mexico Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 78. Turkey Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 79. Israel Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 80. GCC Countries Adalimumab (Humira) and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 81. Adalimumab (Humira) and Biosimilar Value Chain
Figure 82. Adalimumab (Humira) and Biosimilar Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed